Search research articles
Contact Us
Filters
Showing results (1-10 of 67) with videos related to
Page
of 7
Sort By:
Lancet (London, England)
|
April 22, 1995
Transient hypoxaemia during neutrophil recovery in febrile patients
K White, J Cebon
Current Opinion in Hematology
|
May 1, 1994
Measurement and clinical significance of circulating hematopoietic growth factor levels
J Cebon, J Layton
Lancet (London, England)
|
May 1, 1997
Clinical promise of tumour immunology
A M Scott, J Cebon
Blood
|
December 1, 1989
Characterization of the clinical effects after the first dose of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor
G J Lieschke, J Cebon, G Morstyn
Biochemical Society Symposium
|
January 1, 1989
Haemopoietic growth factor control of normal and neoplastic cellular proliferation
A W Burgess, J Cebon, S Smith
Leukemia & Lymphoma
|
December 24, 1997
Viability and quantification of progenitor cells in venesected blood from patients receiving escalated-dose epirubicin and cyclophosphamide with G-CSF for lymphoma: potential role in further increasing dose-intensity
E O'Flaherty, J Cebon, A P Grigg
The Australasian Journal of Dermatology
|
June 1, 1997
Immunotherapy of melanoma: targeting defined antigens
J Cebon, D MacGregor, A Scott, et al.
Australian and New Zealand Journal of Medicine
|
August 1, 1985
A 70 year old man with portal hypertension
F J Dudley, J Cebon, H J Ireton
British Journal of Haematology
|
February 1, 1994
Endogenous haemopoietic growth factors in neutropenia and infection
J Cebon, J E Layton, D Maher, et al.
The Lancet. Oncology
|
March 22, 2002
The use of dendritic cells in cancer therapy
M Jefford, E Maraskovsky, J Cebon, et al.
Page
of 7
Search research articles
Search
Showing results (1-10 of 67) with videos related to
Sort By:
Page
of 7
Lancet (London, England)
|
April 22, 1995
Transient hypoxaemia during neutrophil recovery in febrile patients
K White, J Cebon
Current Opinion in Hematology
|
May 1, 1994
Measurement and clinical significance of circulating hematopoietic growth factor levels
J Cebon, J Layton
Lancet (London, England)
|
May 1, 1997
Clinical promise of tumour immunology
A M Scott, J Cebon
Blood
|
December 1, 1989
Characterization of the clinical effects after the first dose of bacterially synthesized recombinant human granulocyte-macrophage colony-stimulating factor
G J Lieschke, J Cebon, G Morstyn
Biochemical Society Symposium
|
January 1, 1989
Haemopoietic growth factor control of normal and neoplastic cellular proliferation
A W Burgess, J Cebon, S Smith
Leukemia & Lymphoma
|
December 24, 1997
Viability and quantification of progenitor cells in venesected blood from patients receiving escalated-dose epirubicin and cyclophosphamide with G-CSF for lymphoma: potential role in further increasing dose-intensity
E O'Flaherty, J Cebon, A P Grigg
The Australasian Journal of Dermatology
|
June 1, 1997
Immunotherapy of melanoma: targeting defined antigens
J Cebon, D MacGregor, A Scott, et al.
Australian and New Zealand Journal of Medicine
|
August 1, 1985
A 70 year old man with portal hypertension
F J Dudley, J Cebon, H J Ireton
British Journal of Haematology
|
February 1, 1994
Endogenous haemopoietic growth factors in neutropenia and infection
J Cebon, J E Layton, D Maher, et al.
The Lancet. Oncology
|
March 22, 2002
The use of dendritic cells in cancer therapy
M Jefford, E Maraskovsky, J Cebon, et al.
Page
of 7